THER 0.00 Theralink Technologies, Inc.
Range: | 1.0E-4-0.0035 | Vol Avg: | 2253162 | Last Div: | 0 | Changes: | 0 |
Beta: | 19.71 | Cap: | 0.00B | Currency: | USD | Exchange: | PNK |
Sector: | Healthcare | IPO: | Thu Apr 01 2010 | Empoloyees: | 16 |
CUSIP: | 88339Q109 | CIK: | 0001362703 | ISIN: | US88339Q1094 | Country: | US |
CEO: | Mr. Andrew Albert Kucharchuk M.B.A. | Website: | https://theralink.com |
Theralink Technologies, Inc., a commercial-stage precision medicine and molecular data-generating company, engages in the development and commercialization of novel cancer immunotherapy products. The company through its patented phosphoprotein and protein biomarker platform, and laboratory developed test technology targets multiple areas of oncology and drug development. It provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to FDA-approved and investigational drug treatments. The company's data-generating assays provide actionable information for physicians, patients, and biopharmaceutical companies in the area of oncology. Theralink Technologies, Inc. was formerly known as OncBioMune Pharmaceuticals, Inc. and changed its name to Theralink Technologies, Inc. in September 2020. The company is headquartered in Golden, Colorado.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.